Search Results

Divalproex Sodium 100 mg  | 99.84%

TargetMol

Divalproex Sodium binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It also is an HDAC inhibitor. Divalproex Sodium is a stable coordination compound comprised […]

More Information Supplier Page

Dexamethasone Sodium Phosphate 200 mg  | 99.83%

TargetMol

Dexamethasone, an interleukin receptor modulator, has anti-inflammatory and immunosuppressant effects. It belongs to a potent glucocorticoid class of steroid synthetic drugs.

More Information Supplier Page

Bosentan 25 mg  | Purity Not Available

TargetMol

Bosentan is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan […]

More Information Supplier Page

Onvansertib 200 mg  | 97.01%

TargetMol

Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.

More Information Supplier Page

Onvansertib 100 mg  | 97.01%

TargetMol

Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.

More Information Supplier Page

Onvansertib 25 mg  | 97.01%

TargetMol

Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.

More Information Supplier Page

Onvansertib 2 mg  | 97.01%

TargetMol

Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.

More Information Supplier Page

Ledipasvir 25 mg  | 99.46%

TargetMol

Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.

More Information Supplier Page